Imbalance of interleukin-18 and interleukin-18 binding protein in patients with IgA nephropathy implicating renal vasculopathy

Clinical Laboratory

Volumn 61, Issue 1-2, 2015, Pages 23-30

  Shimizu, Chie ^a   Matsumoto, Koichi ^a   Fujita, Takayuki ^a   Fuke, Yoshinobu ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

IgA nephropathy; IL 18 IL 18BP imbalance; Interleukin 18; Interleukin 18 binding protein

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 18 PROTEIN, HUMAN; INTERLEUKIN-18 BINDING PROTEIN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOPATHOGENESIS; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; RENOVASCULAR DISEASE; YOUNG ADULT; ARTERIOSCLEROSIS; BLOOD; CASE CONTROL STUDY; KIDNEY; PATHOLOGY; VASCULARIZATION;

ADULT; AGED; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; KIDNEY; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84924810427     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2014.140515     Document Type: Article

References (21)

1. Nonaka-Takahashi S, Fujita T, Takahashi T, Wada Y, Satomura A, Matsumoto A. TGF-beta1 and CTGF mRNAs are correlated with urinary protein level in IgA nephropathy. Journal of Nephrology 2008;21:53-63.
2. Matsumoto K, Fukuda N, Abe M, Fujita T. Dendritic cells and macrophages in kidney disease. Clinical and Experimental Nephrology 2010;14:1-11.
3. Lim CS, Zheng S, Kim YS, et al. Th1/Th2 predominance and proinflammatory cytokines determine the clinicopathological severity of IgA nephropathy. Nephrology Dialysis Transplantation 2001;16:269-75.
4. Reddy P. Interleukin-18: recent advances. Current Opinion in Hematology 2004;11:405-10.
5. Dinarello CA. IL-18: A Thl-inducing, proinflammatory cytokine and new member of the IL-1 family. Journal of Allergy and Clinical Immunology 1999;103:11-24.
6. Novik D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Thl cytokine response. Immunity 1999;10:127-36.
7. Yellayi S, Braun S, Domingues HG.et al. Cloning and characterization of rhesus IL-18 binding protein, a natural antagonist to IL-18. Cytokine 2010;51:232-9.
8. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. American Journal of Kidney Disease 2000;36:227-37.
9. Tisher CC, Brenner BM. Renal pathology with clinical and functional correlations. Lippincott: Williams & Wilkins, Philadelphia.
10. Mallat Z, Corbaz A, Scoazec A, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circulation Research 2001;89:e41-5.
11. Coppo R, Feehally J. Is progression of IgA nephropathy conditioned by genes regulating atherosclerosis damage? Nephrology Dialysis Transplantation 2009;24:3573-5.
12. Tsioufis C, Dimitriadis K, Taxiarchou E, et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. American Journal of Hypertension 2006;19:462-6.
13. Reddy VS, Harskamp RE, van Ginkel MW, et al. Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. Journal of Cell Physiology 2008,215;697-707.
14. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arteriosclerosis Thrombosis and Vascular Biology 2005;25:791-6.
15. Ruotsalainen E, Vauhkonen I, Salmenniemi U, et al. Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects. Atherosclerosis 2008;197:271-7.
16. Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler M, Kaplan MJ. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 2011;187:6143-56.
17. Rabkin SW: The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 2009,6:192-9.
18. Gauer S, Sichler O, Obermüller N, et al. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int 2007;72:1081-7.
19. Fujita T, Shimizu C, Fuke Y, et al. Serum interleukin-18 binding protein increases with behavior different from IL-18 in patients with diabetic nephropathy. Diabetes Res Clin Pract 2011;92:e66-9.
20. Fujita T, Ogihara N, Kamura Y, et al. Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol 2012;49:111-7.
21. Shimizu C, Fujita T, Fuke Y, et al. High circulating levels of interleukin-18 binding protein indicate the severity of glomerular involvement in systemic lupus erythematosus. Mod Rheumatol 2012;22:73-9.